0001415889-24-007569.txt : 20240311 0001415889-24-007569.hdr.sgml : 20240311 20240311190553 ACCESSION NUMBER: 0001415889-24-007569 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240307 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Sanj K CENTRAL INDEX KEY: 0001532218 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 24739696 MAIL ADDRESS: STREET 1: C/O KINIKSA PHARMACEUTICALS, LTD. STREET 2: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4-03112024_110346.xml X0508 4 2024-03-07 0001730430 Kiniksa Pharmaceuticals, Ltd. KNSA 0001532218 Patel Sanj K C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM 11 BERMUDA true true false false CHAIRMAN & CEO 1 Class A Common Share 2024-03-07 4 S 0 65012 21.02 D 0 I Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Class A Common Share 109795 I Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 Class A Common Share 52516 D This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.00 and $21.145. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Madelyn Zeylikman, Attorney-in-Fact 2024-03-11